TLSI:NASDAQTriSalus Life Sciences, Inc. Analysis
Data as of 2026-09-01 - not real-time
$4.95
Latest Price
9/10Risk
Risk Level: High
Executive Summary
TriSalus Life Sciences, Inc. trades at $4.95, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Across the trailing 30 sessions it gained 14.8%. RSI sits at 49.6, which reads as neutral, and MACD momentum is bearish. Recent trading has carved out support near $4.44 and resistance around $5.91.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 102.0% above the current price.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 58.4%, a beta of 1.21 and a maximum drawdown of 66.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 102.0% above the current price.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 58.4%, a beta of 1.21 and a maximum drawdown of 66.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
This one splits by horizon — hold in the near term, sell further out, at 4/10 long-term conviction.
Top Market Events
WESTMINSTER, Colo., July 16, 2026--TriSalus Life Sciences, Inc. Nasdaq: TLSI the "Company" , an oncology company...TriSalus Life Sciences Inc TLSI reports a 60% revenue increase and strategic growth plans, despite facing operational...Seeking Alpha25dTriSalus Life Sciences, Inc.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading above the 200-day average of 4.82
- MACD momentum is negative
- 30-day price change of +14.8%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 4.82
- Analyst targets imply +102.0% versus the current price
- 30-day volatility of 58.4%
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Negative profit margin of -62.6%
- Analyst targets imply +102.0% versus the current price
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth1.70%
Profit Margin-62.59%
P/E Ratio-19.8
ROA-36.75%
Debt/Equity525.59
P/B Ratio46.3
Op. Cash Flow$-22802000
Free Cash Flow$-10875875
Industry P/E30.4
Technical Analysis
TrendNeutral
RSI49.6
Support$4.44
Resistance$5.91
MA 20$5.21
MA 50$4.67
MA 200$4.82
MACDBearish
VolumeDecreasing
Fear & Greed Index93.93
Valuation
Target Price$10.00
Upside/Downside102.02%
GradeFair
TypeBlend
Risk Assessment
Beta1.21
Volatility58.43%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.